

Chang-Li Wang

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7696018/chang-li-wang-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|-------------------|-----------------------|----------------|----------------|
| 39 papers | 504 citations | 13 h-index | 21 g-index |
| 46 ext. papers | 707 ext. citations | 3.5 avg, IF | 3.4 L-index |

| # | Paper | IF | Citations |
|----|--|-----|-----------|
| 39 | Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2235-2245 | 2.2 | 94 |
| 38 | Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 914-923 | 8.9 | 39 |
| 37 | Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients. <i>World Journal of Surgery</i> , 2012 , 36, 455-62 | 3.3 | 37 |
| 36 | The function of SARI in modulating epithelial-mesenchymal transition and lung adenocarcinoma metastasis. <i>PLoS ONE</i> , 2012 , 7, e38046 | 3.7 | 33 |
| 35 | A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014 , 86, 207-12 | 5.9 | 30 |
| 34 | Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 237-245 | 8.9 | 30 |
| 33 | Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. <i>Annals of Thoracic Surgery</i> , 2013 , 96, 1943-51 | 2.7 | 28 |
| 32 | LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers. <i>Cancer Letters</i> , 2020 , 486, 58-70 | 9.9 | 25 |
| 31 | Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. <i>Oncotarget</i> , 2015 , 6, 15690-703 | 3.3 | 23 |
| 30 | Osteopontin-expressing macrophages in non-small cell lung cancer predict survival. <i>Annals of Thoracic Surgery</i> , 2015 , 99, 1140-8 | 2.7 | 18 |
| 29 | Prognostic value of the lymph node ratio in stage III gastric cancer patients undergoing radical resection. <i>PLoS ONE</i> , 2014 , 9, e96455 | 3.7 | 17 |
| 28 | Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2935-2942 | 2.2 | 16 |
| 27 | Claudin-1 correlates with poor prognosis in lung adenocarcinoma. <i>Thoracic Cancer</i> , 2016 , 7, 556-563 | 3.2 | 13 |
| 26 | Claudin-3 expression increases the malignant potential of lung adenocarcinoma cells: role of epidermal growth factor receptor activation. <i>Oncotarget</i> , 2017 , 8, 23033-23047 | 3.3 | 13 |
| 25 | Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis. <i>Chinese Medical Journal</i> , 2013 , 126, 1683-8 | 2.9 | 13 |
| 24 | Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). <i>Translational Lung Cancer Research</i> , 2019 , 8, 1163-1173 | 4.4 | 9 |
| 23 | Urinary malate dehydrogenase 2 is a new biomarker for early detection of non-small-cell lung cancer. <i>Cancer Science</i> , 2021 , 112, 2349-2360 | 6.9 | 7 |

| | | | |
|----|--|-----|---|
| 22 | Alteration in gene expression profiles of thymoma: Genetic differences and potential novel targets. <i>Thoracic Cancer</i> , 2019 , 10, 1129-1135 | 3.2 | 6 |
| 21 | Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis. <i>EBioMedicine</i> , 2020 , 53, 102689 | 8.8 | 6 |
| 20 | The preoperative platelet distribution width: A predictive factor of the prognosis in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 918-927 | 3.2 | 5 |
| 19 | A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018 , 7, 428-436 | 4.4 | 5 |
| 18 | Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 3234-3242 | 3.2 | 5 |
| 17 | A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017 , 2, e000174 | 6 | 3 |
| 16 | Survival study of neoadjuvant versus adjuvant chemotherapy with docetaxel combined carboplatin in resectable stage IB to IIIA non-small lung cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7537-7537 | 2.2 | 3 |
| 15 | Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 1469-1488 | 3.2 | 3 |
| 14 | Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation. <i>Molecular Oncology</i> , 2021 , 15, 1130-1145 | 7.9 | 3 |
| 13 | Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2021 , 12, 2698-2709 | 3.2 | 3 |
| 12 | TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1509-1519 | 4.9 | 2 |
| 11 | Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e19161-e19161 | 2.2 | 2 |
| 10 | Bevacizumab-Induced Mitochondrial Dysfunction, Endoplasmic Reticulum Stress, and ERK Inactivation Contribute to Cardiotoxicity. <i>Oxidative Medicine and Cellular Longevity</i> , 2021 , 2021, 5548130 | 6.7 | 2 |
| 9 | Validation of the Chinese version of EORTC QLQ-BM22 in patients with bone metastases. <i>Supportive Care in Cancer</i> , 2016 , 24, 1019-24 | 3.9 | 1 |
| 8 | miR-31-5p modulates cell progression in lung adenocarcinoma through TNS1/p53 axis.. <i>Strahlentherapie Und Onkologie</i> , 2022 , 198, 304 | 4.3 | 1 |
| 7 | Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stageIB-IIIA non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8508-8508 | 2.2 | 1 |
| 6 | Sorting and gene mutation verification of circulating tumor cells of lung cancer with epidermal growth factor receptor peptide lipid magnetic spheres. <i>Thoracic Cancer</i> , 2020 , 11, 2887-2895 | 3.2 | 1 |
| 5 | Tumor Differentiation and Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery. <i>Cancer Management and Research</i> , 2020 , 12, 12549-12556 | 3.6 | 1 |

- 4 CITED4 enhances the metastatic potential of lung adenocarcinoma. *Thoracic Cancer*, **2021**, 12, 1291-1303.2 1
- 3 Identification of a DNA damage repair gene-related signature for lung squamous cell carcinoma prognosis.. *Thoracic Cancer*, **2022**, 13, 1-10.3.2 1
- 2 The role of chemokine receptor CXCR7 in lung cancer. *Clinical Oncology and Cancer Research*, **2010**, 7, 342-346
- 1 Prognostic factors and combined histologies in 205 resected small cell lung cancer (SCLC) patients.. *Journal of Clinical Oncology*, **2017**, 35, e20009-e20009 2.2